Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended

2024-511067-29-00 IgA Nephropathy 5 2021-01-25
A long-term study to assess the safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia (an autoimmune di… Ended

2024-511504-17-00 Primary immune thrombocytopenia 5 2020-12-15
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Bullous Pemphigoid 10 2020-11-11
Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended

2024-514090-21-00 Aetiological treatment of moderate - severe intermitten 5 2020-08-05
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended

2023-509801-59-00 Alopecia areata 5 2020-07-09
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r… Ended

2024-518265-10-01 Relapse/ refractory acute Leukemia 1 2020-06-03
Long-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Ended

2023-503600-83-00 Moderate to Severe Plaque Psoriasis 5 2020-05-27
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 C3 glomerulopathy 4 2020-01-01
A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended

2023-506528-95-00 Psoriatic Arthritis 5 2019-11-21
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended

2024-517309-95-00 -Peripheral neuropathy clinically defined: *Pure sensit 5 2019-06-19
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Giant Cell Arteritis 5 2019-04-05
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patien… Ended

2023-508424-34-00 Moderate to Severe Plaque Type Psoriasis 5 2019-02-11
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended

2023-507330-24-00 Chronic Graft Versus Host Disease (cGVHD) 9 2019-02-07
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Moderate and Severe Atopic Dermatitis 5 2019-01-09
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Moderate and Severe Atopic Dermatitis 5 2018-12-10
ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Ther… Ended

2024-519336-16-00 Relapsed or Refractory Angioimmunoblastic T cell Lympho 10 2018-10-31
A clinical trial to find out if VAY736 can help people with autoimmune hepatitis, a disease where your immune system attacks your own liver Ended

2023-508859-39-00 Autoimmune hepatitis 10 2018-02-15
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended

2024-511714-20-00 Multiple Myeloma 4 2018-01-30
A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patient… Ended

2024-512790-27-00 Treatment of X-linked Chronic Granulomatous Disease 7 2016-04-19
A Long-Term, Open-Label, Study for Treatment of JIA Ended

2023-509651-14-00 Juvenile Idiopathic Arthritis (JIA) 10 2013-04-03
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended

2024-512730-15-00 Systemic Lupus Erythematosus 4 2012-09-14